SG10201700775YA - A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease - Google Patents

A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease

Info

Publication number
SG10201700775YA
SG10201700775YA SG10201700775YA SG10201700775YA SG10201700775YA SG 10201700775Y A SG10201700775Y A SG 10201700775YA SG 10201700775Y A SG10201700775Y A SG 10201700775YA SG 10201700775Y A SG10201700775Y A SG 10201700775YA SG 10201700775Y A SG10201700775Y A SG 10201700775YA
Authority
SG
Singapore
Prior art keywords
related disease
prevention
treating
preventing
treatment
Prior art date
Application number
SG10201700775YA
Inventor
Kenji Shinomiya
Koichiro Yoneyama
Norihito Shibahara
Yoshinori Tsuboi
Taku Fukuzawa
Kenta Haraya
Zenjiro Sampei
Katrijn Bogman
Jean Eric Charoin
Original Assignee
Chugai Pharmaceutical Co Ltd
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd, Hoffmann La Roche filed Critical Chugai Pharmaceutical Co Ltd
Priority to SG10201700775YA priority Critical patent/SG10201700775YA/en
Priority to KR1020237009640A priority patent/KR20230043247A/en
Priority to MX2019007749A priority patent/MX2019007749A/en
Priority to ES18710159T priority patent/ES2947735T3/en
Priority to RU2019126664A priority patent/RU2786053C2/en
Priority to CR20220563A priority patent/CR20220563A/en
Priority to CR20190403A priority patent/CR20190403A/en
Priority to KR1020197004219A priority patent/KR102365871B1/en
Priority to US16/480,047 priority patent/US20190367599A1/en
Priority to AU2018215039A priority patent/AU2018215039A1/en
Priority to PCT/JP2018/003193 priority patent/WO2018143266A1/en
Priority to BR112019015426-4A priority patent/BR112019015426A2/en
Priority to PL18710159.7T priority patent/PL3577135T3/en
Priority to JP2018014743A priority patent/JP6383122B2/en
Priority to TW107103450A priority patent/TWI658834B/en
Priority to IL307593A priority patent/IL307593A/en
Priority to CN201880005975.XA priority patent/CN110167961A/en
Priority to EP23165354.4A priority patent/EP4223774A3/en
Priority to CA3051389A priority patent/CA3051389A1/en
Priority to SG10201908697X priority patent/SG10201908697XA/en
Priority to KR1020227005327A priority patent/KR102514175B1/en
Priority to EP18710159.7A priority patent/EP3577135B1/en
Priority to SG11201801401UA priority patent/SG11201801401UA/en
Priority to KR1020187009861A priority patent/KR101949891B1/en
Priority to TW108110617A priority patent/TWI828672B/en
Priority to JP2018118937A priority patent/JP7141865B2/en
Publication of SG10201700775YA publication Critical patent/SG10201700775YA/en
Priority to MX2022012931A priority patent/MX2022012931A/en
Priority to PH12019501706A priority patent/PH12019501706A1/en
Priority to IL268327A priority patent/IL268327A/en
Priority to US16/928,129 priority patent/US20200407432A1/en
Priority to JP2022144425A priority patent/JP2022168209A/en
Priority to US18/181,641 priority patent/US20230250162A1/en

Links

Abstract

A PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OR PREVENTION OF A C5-RELATED DISEASE AND A METHOD FOR TREATING OR PREVENTING A C5-RELATED DISEASE The present invention is related to a pharmaceutical composition for use in the treatment or prevention of a C5-related disease and a method for treating or preventing a C5-related diseasedosage and administration of anti-C5 antibody. [No suitable figure]
SG10201700775YA 2017-01-31 2017-01-31 A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease SG10201700775YA (en)

Priority Applications (32)

Application Number Priority Date Filing Date Title
SG10201700775YA SG10201700775YA (en) 2017-01-31 2017-01-31 A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease
IL307593A IL307593A (en) 2017-01-31 2018-01-31 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
KR1020187009861A KR101949891B1 (en) 2017-01-31 2018-01-31 Pharmaceutical compositions for treating or preventing C5-related diseases and methods for treating or preventing C5-related diseases
ES18710159T ES2947735T3 (en) 2017-01-31 2018-01-31 A pharmaceutical composition for use in the treatment or prevention of diseases related to C5
RU2019126664A RU2786053C2 (en) 2017-01-31 2018-01-31 Pharmaceutical composition for use for treatment or prevention of c5-related disease and method for treatment or prevention of c5-related disease
CR20220563A CR20220563A (en) 2017-01-31 2018-01-31 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
CR20190403A CR20190403A (en) 2017-01-31 2018-01-31 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EP23165354.4A EP4223774A3 (en) 2017-01-31 2018-01-31 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
US16/480,047 US20190367599A1 (en) 2017-01-31 2018-01-31 Pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
AU2018215039A AU2018215039A1 (en) 2017-01-31 2018-01-31 A pharmaceutical composition for use in the treatment or prevention of a C5-related disease and a method for treating or preventing a C5-related disease
PCT/JP2018/003193 WO2018143266A1 (en) 2017-01-31 2018-01-31 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
BR112019015426-4A BR112019015426A2 (en) 2017-01-31 2018-01-31 PHARMACEUTICAL COMPOSITION FOR USE IN TREATING OR PREVENTING A C5-RELATED DISEASE AND A METHOD FOR TREATING OR PREVENTING A C5-RELATED DISEASE
PL18710159.7T PL3577135T3 (en) 2017-01-31 2018-01-31 A pharmaceutical composition for use in the treatment or prevention of c5-related diseases
JP2018014743A JP6383122B2 (en) 2017-01-31 2018-01-31 Pharmaceutical composition for treatment or prevention of C5-related diseases and method for treating or preventing C5-related diseases
TW107103450A TWI658834B (en) 2017-01-31 2018-01-31 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
KR1020237009640A KR20230043247A (en) 2017-01-31 2018-01-31 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
CN201880005975.XA CN110167961A (en) 2017-01-31 2018-01-31 Method for treating or preventing the pharmaceutical composition of C5 related disease and treating or preventing C5 related disease
KR1020197004219A KR102365871B1 (en) 2017-01-31 2018-01-31 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
CA3051389A CA3051389A1 (en) 2017-01-31 2018-01-31 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
SG10201908697X SG10201908697XA (en) 2017-01-31 2018-01-31 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
KR1020227005327A KR102514175B1 (en) 2017-01-31 2018-01-31 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EP18710159.7A EP3577135B1 (en) 2017-01-31 2018-01-31 A pharmaceutical composition for use in the treatment or prevention of c5-related diseases
SG11201801401UA SG11201801401UA (en) 2017-01-31 2018-01-31 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX2019007749A MX2019007749A (en) 2017-01-31 2018-01-31 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease.
TW108110617A TWI828672B (en) 2017-01-31 2018-01-31 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
JP2018118937A JP7141865B2 (en) 2017-01-31 2018-06-22 Pharmaceutical compositions for treating or preventing C5-related diseases and methods for treating or preventing C5-related diseases
MX2022012931A MX2022012931A (en) 2017-01-31 2019-06-26 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease.
PH12019501706A PH12019501706A1 (en) 2017-01-31 2019-07-24 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
IL268327A IL268327A (en) 2017-01-31 2019-07-29 A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
US16/928,129 US20200407432A1 (en) 2017-01-31 2020-07-14 Pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
JP2022144425A JP2022168209A (en) 2017-01-31 2022-09-12 Pharmaceutical composition for treating or preventing c5 related disease and method for treating or preventing c5 related disease
US18/181,641 US20230250162A1 (en) 2017-01-31 2023-03-10 Pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG10201700775YA SG10201700775YA (en) 2017-01-31 2017-01-31 A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease

Publications (1)

Publication Number Publication Date
SG10201700775YA true SG10201700775YA (en) 2018-08-30

Family

ID=63286965

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201700775YA SG10201700775YA (en) 2017-01-31 2017-01-31 A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease

Country Status (1)

Country Link
SG (1) SG10201700775YA (en)

Similar Documents

Publication Publication Date Title
PH12019501706A1 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX2021000071A (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease.
MX2019011117A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof.
UA118453C2 (en) Modulation of tumor immunity
MX2020001774A (en) Compositions and methods for treating cholestatic disease.
PH12021550226A1 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX2021002321A (en) Novel methods.
MX2021011110A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack.
MX2019009586A (en) Compositions and methods for treating disease associated with permeability of intestinal epithelium.
MX2018008645A (en) 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives.
MX2020001164A (en) Composition for use in the prevention and/or treatment of oncologic treatment induced orogastrointestinal mucositis.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
MX2017004723A (en) Pharmaceutical composition for use in the treatment or prevention of vitamin and mineral deficiencies in patients which have been subjected to gastric bypass-surgery.
HK1246639A1 (en) Oral pharmaceutical composition and method of treating or preventing disease
MX2019004200A (en) Combination therapy.
IL288636A (en) Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
MX368735B (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine.
SG10201700775YA (en) A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease
MX2021001228A (en) Composition for use in the prevention and/or treatment of the genitourinary mucosa.
MX2020005310A (en) Combination product comprising dicycloplatin and preparation method and use thereof.
SG10201705954VA (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
WO2018030881A3 (en) Use of thyroid hormone for treatment of choroidal disease
IL288600A (en) Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab